Physician profile
Daniel E Gershon
NPI 1215929203
$2,458.30
in general payments reported to CMS, 2019-2025
30 companies · $520 in 2025
The $520 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $84.12 · 2021: $198 · 2022: $130 · 2023: $353 · 2024: $504 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.47 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $523.10 | 2022-2025 | Azstarys |
| Pfizer INC. | $346.73 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $239.96 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $197.78 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $149.13 | 2019-2025 | Doc Band |
| Biomarin Pharmaceutical INC. | $129.76 | 2023-2025 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $105.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $91.94 | 2019-2025 | Pediarix, Bexsero, Penmenvy |
| Sanofi-Aventis U.S. LLC | $91.46 | 2025 | |
| Shire North American Group INC | $80.11 | 2019 | |
| Amgen INC. | $59.63 | 2019 | |
| Novo Nordisk INC | $50.38 | 2019 | |
| Tris Pharma INC | $43.07 | 2019 | |
| Sanofi Pasteur INC. | $37.21 | 2019-2024 | |
| Adlon Therapeutics L.P. | $37.15 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.82 | 2025 | Jornay Pm |
| Abbvie INC. | $27.34 | 2019-2020 | |
| Neos Therapeutics, LP | $25.75 | 2019-2021 | |
| Travere Therapeutics, INC. | $25.27 | 2023 | Cholbam |
| Merck Sharp & Dohme LLC | $22.94 | 2019-2020 | |
| Mirum Pharmaceuticals, INC. | $22.81 | 2023 | |
| Azurity Pharmaceuticals, INC. | $19.12 | 2025 | Alvesco |
| Novartis Pharmaceuticals Corporation | $14.07 | 2019 | |
| Antares Pharma, INC. | $13.81 | 2019 | |
| Kaleo, INC. | $12.57 | 2022 | |
| Intersect Ent, INC. | $12.05 | 2019 | |
| Genentech USA, INC. | $11.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.78 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gershon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.